Nitin R. Patel

发表

The future of drug development: advancing clinical trial design

C. Mehta, J. Orloff, F. Douglas, 2009, Nature Reviews Drug Discovery.

Designing Phase 2 Trials Based on Program-Level Considerations: A Case Study for Neuropathic Pain

Nitin R. Patel, C. Chuang-Stein, J. Bolognese, 2012 .

Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies

Frank Bretz, Joshua R. Smith, Chyi-Hung Hsu, 2010 .

The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions

Sarah Garner, Mark R. Trusheim, Gigi Hirsch, 2014 .

Impact of Phase 2b Strategies on Optimization of Drug Development Programs

C. Jennison, Nitin R. Patel, C. Burman, 2015 .

Optimizing adaptive design for Phase 2 dose-finding trials incorporating long-term success and financial considerations: A case study for neuropathic pain.

Nitin R. Patel, J. Bolognese, Jia Jia, 2017, Contemporary clinical trials.

Effective Drug Supply for Adaptive Clinical Trials

Nitin R. Patel, Tom Parke, Weili He, 2015, Therapeutic innovation & regulatory science.

A Simulation Study to Compare New Adaptive Dose–Ranging Designs

Frank Bretz, Joshua R. Smith, José Pinheiro, 2010 .

A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk

Zoran Antonijevic, Nitin R Patel, Suresh Ankolekar, 2013, Statistics in medicine.

A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs

Nitin R Patel, Suresh Ankolekar, Nitin R. Patel, 2007, Statistics in medicine.

TRIAL DESIGN SIMULATION : A Critical Tool in Adaptive

Nitin R. Patel, B. Byrom, Graham Nicholls, 2009 .